PLX-4720

Name: PLX-4720
Brand: Selleck Chemicals
SKU: S1152
Rating: 5 (129 reviews)

For research use only.

Catalog No.S1152

129 publications

CAS No. 918505-84-7

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

Selleck's PLX-4720 has been cited by 129 publications

Cancer Cell, 2020, 37(1):85-103

PubMed: 31935375 ( click the link to review the publication )

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Nature, 2017, 548(7667):343-346

PubMed: 28792927 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )

Nature, 2015, 517(7536):583-8

PubMed: 25494202 ( click the link to review the publication )

Cell, 2015, 160(1-2):161-76

PubMed: 25594179 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cancer Discov, 2014, 4(7):816-27

PubMed: 24771846 ( click the link to review the publication )

Nature, 2013, 6;498(7452):109-12.

PubMed: 23685455 ( click the link to review the publication )

Cell, 2013, 29;154(5):1036-1046.

PubMed: 23993095 ( click the link to review the publication )

Nat Biotechnol, 2013, 31(7):630-7

PubMed: 23811600 ( click the link to review the publication )

Cancer Discov, 2013, 3(3):350-62

PubMed: 23288408 ( click the link to review the publication )

Nature, 2012, 26;483(7387):100-3.

PubMed: 22281684 ( click the link to review the publication )

Sci Adv, 2020, 6(9):eaax3223

PubMed: 32133394 ( click the link to review the publication )

Genomics Proteomics Bioinformatics, 2020, 12 pii: S1672-0229(20)30052-8

PubMed: 32413516 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2020, 10.1111/pcmr.12932

PubMed: 33000894 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):191

PubMed: 32913191 ( click the link to review the publication )

Cancer Discov, 2020, 4;CD-20-0329

PubMed: 32499221 ( click the link to review the publication )

J Transl Med, 2020, 11;18(1):192

PubMed: 32393282 ( click the link to review the publication )

J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Transl Oncol, 2020, 13(2):355-364

PubMed: 31887630 ( click the link to review the publication )

Cell Rep, 2020, 30(2):510-524

PubMed: 31940493 ( click the link to review the publication )
Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, S1097-2765(19)30838-X

PubMed: 31836388 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5232

PubMed: 31745079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5167

PubMed: 31727888 ( click the link to review the publication )

Cell Syst, 2019, 9(4):366-374

PubMed: 31521607 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Thyroid, 2019, 29(1):79-92

PubMed: 30398411 ( click the link to review the publication )

Oncogene, 2019, 38(22):4384-4396

PubMed: 30710146 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(12):2506-2516

PubMed: 31229500 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)

PubMed: 31083627 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):480-494

PubMed: 30582770 ( click the link to review the publication )

Mol Cell Proteomics, 2019, 18(6):1096-1109

PubMed: 30890564 ( click the link to review the publication )

Transl Oncol, 2019, 12(7):932-950

PubMed: 31096110 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(7):1426-1435

PubMed: 31063355 ( click the link to review the publication )

Genes Genomics, 2019, 41(11):1273-1280

PubMed: 31388978 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1482

PubMed: 29662054 ( click the link to review the publication )

Genome Res, 2018, 28(9):1353-1363

PubMed: 30061114 ( click the link to review the publication )

J Control Release, 2018, 277:48-56

PubMed: 29550398 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10902

PubMed: 30026510 ( click the link to review the publication )
ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Med Sci (Basel), 2018, 6(1)

PubMed: 29304009 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )

Biophys J, 2018, 114(6):1499-1511

PubMed: 29590606 ( click the link to review the publication )

Nat Commun, 2017, 8(1):607

PubMed: 28928360 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(14):3953-3965

PubMed: 28096271 ( click the link to review the publication )

Oncogene, 2017, 36(32):4585-4596

PubMed: 28368422 ( click the link to review the publication )

Br J Cancer, 2017, 116(8):1065-1076

PubMed: 28301874 ( click the link to review the publication )

Mol Oncol, 2017,

PubMed: 28182330 ( click the link to review the publication )

Neoplasia, 2017, 19(11):932-940

PubMed: 28963969 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2017, 154:350-356

PubMed: 28365424 ( click the link to review the publication )

Am J Physiol, Cell Physiol, 2017,

PubMed: 28100485 ( click the link to review the publication )

Cancer Res Treat, 2017, 49(4):947-959

PubMed: 28052651 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(2):219-237

PubMed: 27974353 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115140-115152

PubMed: 29383148 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2016,

PubMed: 26787892 ( click the link to review the publication )

Cell Rep, 2016, 10.1016/j.celrep.2016.05.064

PubMed: 27320919 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )

Oncogene, 2016, 35(20):2675-80

PubMed: 26119932 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(20):2612-25

PubMed: 27503857 ( click the link to review the publication )

Pharm Biol, 2016, 54(4):732-9

PubMed: 26931349 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2876-2888

PubMed: 27571413 ( click the link to review the publication )

Oncotarget, 2016, 7(50):81995-82012

PubMed: 27835901 ( click the link to review the publication )
Oncotarget, 2016, 7(31):49597-49610

PubMed: 27391062 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Nat Struct Mol Biol, 2015, 22(1):37-43

PubMed: 25437913 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1652-64

PubMed: 25617424 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(6):E536-45

PubMed: 25624498 ( click the link to review the publication )

Cancer Res, 2015, 75(21):4573-81

PubMed: 26363009 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 10.1111/pcmr.12364

PubMed: 25728708 ( click the link to review the publication )

Front Oncol, 2015, 10.3389/fonc.2015.00095

PubMed: ( click the link to review the publication )

Front Oncol, 2015, 5:95

PubMed: 26029660 ( click the link to review the publication )

J Cell Physiol, 2015, 10.1002/jcp.24888

PubMed: 25600161 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Exp Cell Res, 2015, 1;338(2):127-35

PubMed: 26384551 ( click the link to review the publication )

Biomol Ther (Seoul), 2015, 23(4):320-6

PubMed: 26157547 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26172302 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(9):2410-23

PubMed: 24573550 ( click the link to review the publication )

Cancer Res, 2014, 74(23):7079-89

PubMed: 25320010 ( click the link to review the publication )

Cancer Res, 2014, 74(15):4122-32

PubMed: 25035390 ( click the link to review the publication )

Mol Syst Biol, 2014, 10:772

PubMed: 25538140 ( click the link to review the publication )

Cell Rep, 2014, 10.1016/j.celrep.2014.10.024

PubMed: ( click the link to review the publication )
Cell Rep, 2014, 9(4):1375-86

PubMed: 25456132 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(9):1314-23

PubMed: 25061102 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(5):2598-608

PubMed: 24550330 ( click the link to review the publication )

Biochem J, 2014, 459(3):513-24

PubMed: 24527759 ( click the link to review the publication )

Toxicol Lett, 2014, 10.1111/cmi.12305

PubMed: 24779413 ( click the link to review the publication )

J Pharm Pharm Sci, 2014, 17(1):154-68

PubMed: 24735766 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(1):e87457

PubMed: 24475291 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101286

PubMed: 24983357 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(16):4383-91

PubMed: 23812671 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 27(1):124-33

PubMed: 24112705 ( click the link to review the publication )

Oncogenesis, 2013, 2:e44

PubMed: 23588493 ( click the link to review the publication )

Clin Endocrinol, 2013, 81(1):109-16

PubMed: 24382015 ( click the link to review the publication )

Transl Oncol, 2013, 6(4):470-81

PubMed: 23908690 ( click the link to review the publication )

Mol Cell Biochem, 2013, 372(1-2):65-74

PubMed: 22941213 ( click the link to review the publication )

J Chromatogr B Analyt Technol Biomed Life Sci, 2013, 925:124-8

PubMed: 23537694 ( click the link to review the publication )

J Biomol Screen, 2013, 19(4):526-37

PubMed: 24361645 ( click the link to review the publication )

J Membr Biol, 2013, 247(2):137-45

PubMed: 24258620 ( click the link to review the publication )

Sci Signal, 2013, 6(281):ra51

PubMed: 23800469 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(12):1530-41

PubMed: 24152792 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(12):3316-27

PubMed: 22553342 ( click the link to review the publication )

Genes Dev, 2012, 26(10):1055-69

PubMed: 22549727 ( click the link to review the publication )

Oncogene, 2012, 32(40):4836-44

PubMed: 23208503 ( click the link to review the publication )
J Invest Dermatol, 2012, 132(11):2652-60

PubMed: 22718120 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Biol Chem, 2012, 287(1):91-104

PubMed: 22027819 ( click the link to review the publication )

Biochem J, 2012, 450(2):285-94

PubMed: 23234544 ( click the link to review the publication )

Oncotarget, 2012, 3(12):1688-99

PubMed: 23518796 ( click the link to review the publication )

Mol Biol Cell, 2011, 22(23):4647-56

PubMed: 21976697 ( click the link to review the publication )

PLoS One, 2011, 6(8):e23235

PubMed: 21829721 ( click the link to review the publication )

PLoS One, 2011, 6(11):e26908

PubMed: 22125603 ( click the link to review the publication )

Sci Signal, 2010, 3(149):ra84

PubMed: 21098728 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Targets

C-Raf-1 (Y340D/Y341D) ^[1] (Cell-free assay)	B-Raf (V600E) ^[1] (Cell-free assay)	BRK ^[1] (Cell-free assay)	B-Raf ^[1] (Cell-free assay)
6.7 nM	13 nM	130 nM	160 nM

In vitro

PLX-4720 displays >10 times selectivity against wild type B-Raf, and >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, and Aurora A with IC50 of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-Raf^V600E with IC50 of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-Raf^V600E oncogene, such as COLO205, A375, WM2664, and COLO829 with GI50 of 0.31 μM, 0.50 μM, 1.5 μM, and 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest and apoptosis exclusively in the B-Raf^V600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells. ^[1] PLX-4720 treatment (10 μM) significantly induces >14-fold expression of BIM in the PTEN⁺ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN^- cells to PLX-4720-induced apoptosis. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
DU-4475	NFfOdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTkSlZiUUN3ME2wMlA4PDV5IN88US=>	MWfTRW5ITVJ?
EoL-1-cell	NFnlZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{H1SGlEPTB;MD6xOFE3PiEQvF2=	M{XB[nNCVkeHUh?=
C32	NHX2e\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwMUWxN\|Eh\|ryP	MmHjV2FPT0WU
M14	NY\XbpJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\Eeo9KSzVyPUCuNlE4PTdizszN	MWnTRW5ITVJ?
CP50-MEL-B	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYX3VpRHUUN3ME2wMlI6Pzh2IN88US=>	MVXTRW5ITVJ?
A101D	NYnMVo4yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvqfm1xUUN3ME2wMlMzPTh7IN88US=>	MYnTRW5ITVJ?
G-361	NIrFfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\KV4hzUUN3ME2wMlM1PjN5IN88US=>	MmH5V2FPT0WU
HT-144	NUHSWHF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPVTWM2OD1yLkO2N\|I6KM7:TR?=	MmnQV2FPT0WU
ACN	M1vPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEO4XXdKSzVyPUCuN\|g1PzdizszN	MUfTRW5ITVJ?
COLO-829	M3fWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\JXmlEPTB;MD6zPFk3QCEQvF2=	NXztR\|FnW0GQR1XS
MEL-HO	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zTdGlEPTB;MD60NVE4QSEQvF2=	MoTIV2FPT0WU
SH-4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nuR2lEPTB;MD60NVQzOiEQvF2=	M2nYSXNCVkeHUh?=
SK-MEL-3	NWTkcFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPzXnRKSzVyPUCuOVE2PjhizszN	M4XwW3NCVkeHUh?=
A375	M3z3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnOwTWM2OD1yLk[3N\|U6KM7:TR?=	NVK1RYZ7W0GQR1XS
MMAC-SF	NI\YPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrHd5ZKSzVyPUCuOlg3OTRizszN	NWnlfGlDW0GQR1XS
BHT-101	MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwN{C3NFIh\|ryP	MXPTRW5ITVJ?
K5	NWrVS\|lbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnu2TWM2OD1yLke2NVQ5KM7:TR?=	MUTTRW5ITVJ?
BV-173	M4DSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NED1TINKSzVyPUCuO\|k3PDRizszN	M1TzVXNCVkeHUh?=
RVH-421	NUPxc2J1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTBwOE[3PVYh\|ryP	NHjHdVhUSU6JRWK=
HCC2218	NGDhW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjjcmpKSzVyPUCuPFc5PDRizszN	NFnESplUSU6JRWK=
WM-115	M3O4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIWxO2ZKSzVyPUCuPFg3QTJizszN	MULTRW5ITVJ?
SK-MEL-28	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXVRlFXUUN3ME2xMlA1PTZ7IN88US=>	Mn;iV2FPT0WU
COLO-679	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\1XmZKSzVyPUGuNVA1PjRizszN	MVfTRW5ITVJ?
MZ7-mel	M{\5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjFc4hKSzVyPUGuNVQ6PjNizszN	MmnOV2FPT0WU
SK-MEL-30	NIj2NFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTLTWM2OD1zLkOzN\|g3KM7:TR?=	M2jyO3NCVkeHUh?=
NCI-H209	MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTFwNkC4OkDPxE1?	Mke5V2FPT0WU
HTC-C3	NGfKXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTFwNk[yPVQh\|ryP	MnfBV2FPT0WU
KARPAS-45	NVzW[ZdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTJwMES5O\|gh\|ryP	NV:5T3lEW0GQR1XS
NCI-SNU-5	NHX3NphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmP2TWM2OD1{LkGxPVY6KM7:TR?=	MX;TRW5ITVJ?
KP-4	NXzxe5pzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvXUXFKSzVyPUKuN\|A4QDdizszN	MmjnV2FPT0WU
PA-1	M3fsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PZUmlEPTB;Mj63NlY4OyEQvF2=	MXLTRW5ITVJ?
HuO-3N1	MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHXTWM2OD1{Lki3PVQ3KM7:TR?=	NH[0UWpUSU6JRWK=
NCI-H358	NXi2e5R2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTJwOUKyN\|Ih\|ryP	MkjyV2FPT0WU
CTB-1	NVLrVWhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPTbZRKSzVyPUOuOFAyPzZizszN	NIXvSYdUSU6JRWK=
697	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXJPI9VUUN3ME2zMlU2OjZ4IN88US=>	NGfwbWFUSU6JRWK=
CP66-MEL	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTRwMUW5Nlch\|ryP	M2jTSHNCVkeHUh?=
NB13	M2LOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHpTWM2OD12LkS5NVc6KM7:TR?=	MWrTRW5ITVJ?
DBTRG-05MG	NEW1V3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPaTWM2OD12LkWzN\|I2KM7:TR?=	M4Pac3NCVkeHUh?=
A2058	Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPMTWM2OD12LkeyNVY1KM7:TR?=	MmLWV2FPT0WU
KG-1	NVvuT5B3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HVOGlEPTB;ND63N\|kxQCEQvF2=	NH\ISm5USU6JRWK=
8305C	NED6SXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrhTWM2OD13LkG4O\|Mh\|ryP	M370RnNCVkeHUh?=
RPMI-7951	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4D0OmlEPTB;NT64NFI5OyEQvF2=	M4DUZnNCVkeHUh?=
CHL-1	M2HnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHEPWhKSzVyPUWuPVc3ODNizszN	MWLTRW5ITVJ?
TI-73	M4\xSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jTV2lEPTB;Nj6wNFkxOiEQvF2=	NIHucFhUSU6JRWK=
HT-1080	NIC0e2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PEd2lEPTB;Nj6xNFk1PiEQvF2=	NI\6ZoJUSU6JRWK=
ES5	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLYWFR5UUN3ME22MlE1QTJ2IN88US=>	MYjTRW5ITVJ?
8-MG-BA	M1HRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLCZ3N3UUN3ME22MlE5OTJ7IN88US=>	MmLqV2FPT0WU
NB7	NFTBOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;l[HlKSzVyPU[uNlE{PzNizszN	M3HrZXNCVkeHUh?=
H4	NVflZWl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTZwMkK0PVMh\|ryP	MmC4V2FPT0WU
CAL-72	MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{W1RWlEPTB;Nj60OVQzOyEQvF2=	MojQV2FPT0WU
HCC1806	NX\lV\|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTZwOEG5N\|Eh\|ryP	NGjxNphUSU6JRWK=
BCPAP	NYnKSVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\hVpdKSzVyPUeuNlE4PjRizszN	NV;TWHpQW0GQR1XS
LB2241-RCC	NGewVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTdwM{[5NFch\|ryP	M{X3T3NCVkeHUh?=
COLO-741	NE\WTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRThwMEG2O\|kh\|ryP	M36zNnNCVkeHUh?=
HSC-3	NHnQPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3FTWM2OD16LkC3NFY5KM7:TR?=	MYjTRW5ITVJ?
SW982	MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3Q[olKSzVyPUiuOFE2OTZizszN	MljxV2FPT0WU
GCT	NE\FRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEj1dGJKSzVyPUiuO\|U{OTRizszN	NXHjSZloW0GQR1XS
KY821	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDybXZKSzVyPUmuNFUyPzhizszN	M4K0W3NCVkeHUh?=
JVM-3	MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTlwNU[5PVkh\|ryP	NVyzRWlGW0GQR1XS
RS4-11	NGH3SIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnIdVlKSzVyPUmuOlA1QCEQvF2=	NUTuNmR1W0GQR1XS
VA-ES-BJ	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTFyLkCxOFkh\|ryP	NYL3V25wW0GQR1XS
A431	MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorlTWM2OD1zMD60NlEzKM7:TR?=	MWDTRW5ITVJ?
LXF-289	M4HqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfvOG1uUUN3ME2xNE41PThizszN	M{niNnNCVkeHUh?=
SK-MEL-24	NWmwdYZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nhfWlEPTB;MUCuPFI4PCEQvF2=	M2K1WnNCVkeHUh?=
NOS-1	NWHXbWVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPL[3JoUUN3ME2xNE45PDd{IN88US=>	MUnTRW5ITVJ?
KNS-62	NHfl[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{e5VmlEPTB;MUGuNlQxPCEQvF2=	M{mxbnNCVkeHUh?=
SK-HEP-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknJTWM2OD1zMT6zOVI4KM7:TR?=	NHW2TJNUSU6JRWK=
A3-KAW	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTFzLkexO\|gh\|ryP	M4r0O3NCVkeHUh?=
SK-LU-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjlRmJzUUN3ME2xNk4zPjV3IN88US=>	NV\UXHdkW0GQR1XS
TYK-nu	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzycXNKSzVyPUGyMlM6OzJizszN	M1\lNXNCVkeHUh?=
NMC-G1	NGTMXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTF{Lk[wOlIh\|ryP	MUPTRW5ITVJ?
BB65-RCC	NIW5c5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTF{LkexOlkh\|ryP	MXfTRW5ITVJ?
QIMR-WIL	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHT4WmxKSzVyPUGyMlg5OzNizszN	MkH5V2FPT0WU
D-566MG	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnj2TWM2OD1zMz65OVc3KM7:TR?=	MkDsV2FPT0WU
KYSE-140	M1fEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3KTWM2OD1zND6wO\|U{KM7:TR?=	MXHTRW5ITVJ?
SCC-4	Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnHTWM2OD1zND6zN\|U6KM7:TR?=	MUXTRW5ITVJ?
U251	NGDkWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nsfGlEPTB;MUSuPFQ6OiEQvF2=	MXnTRW5ITVJ?
D-542MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvyVGlKSzVyPUG0MlkzOjJizszN	MX7TRW5ITVJ?
LAMA-84	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPM[pVyUUN3ME2xOE46QTN{IN88US=>	NH;TUZhUSU6JRWK=
NCI-H720	NXX1foNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LqNmlEPTB;MUWuNlY5PCEQvF2=	NVPndHVyW0GQR1XS
DEL	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXzOpBKSzVyPUG1MlQzQTNizszN	NGHxRnlUSU6JRWK=
SBC-1	NInjbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPYSm1WUUN3ME2xOU41OzB3IN88US=>	NFHZ[YVUSU6JRWK=
ECC10	NFrGdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XWZmlEPTB;MUWuOFQ2QCEQvF2=	Mm\tV2FPT0WU
Daoy	NXHWO3BxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrLOoJyUUN3ME2xOU44PjF4IN88US=>	Mn7EV2FPT0WU
SCH	MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV:4UFRbUUN3ME2xOU44QDN3IN88US=>	Ml73V2FPT0WU
MZ2-MEL	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2X3OWlEPTB;MU[uNFY1PiEQvF2=	NFvPPGhUSU6JRWK=
CAL-12T	NFq3R4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDvTWM2OD1zNj60PFYzKM7:TR?=	MnPMV2FPT0WU
KE-37	M3zLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTF4LkixNFch\|ryP	NHjqSY5USU6JRWK=
LS-411N	NUPwNlB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTF5LkGxPEDPxE1?	M2HydHNCVkeHUh?=
NCI-H2228	MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHrTWM2OD1zNz6zNFcyKM7:TR?=	NGLMUXBUSU6JRWK=
SK-MEL-2	NWDTNlR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnG0TWM2OD1zNz60PVY2KM7:TR?=	MkHOV2FPT0WU
HN	NFLSfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIS3W3BKSzVyPUG3MlczPDhizszN	NUW2N3VsW0GQR1XS
NCI-H1648	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HxSmlEPTB;MUeuPFE5KM7:TR?=	MlfnV2FPT0WU
IA-LM	NVjoTFBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnEb4JpUUN3ME2xPE4{OTd{IN88US=>	M2DMbXNCVkeHUh?=
EW-13	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nsfmlEPTB;MUiuOVcxQCEQvF2=	M4HXXnNCVkeHUh?=
YKG-1	MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvVNFZFUUN3ME2xPU42PzFzIN88US=>	MWHTRW5ITVJ?
KNS-81-FD	NUnkdmNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPWe\|FkUUN3ME2xPU42QDV6IN88US=>	M3nkdXNCVkeHUh?=
23132-87	NYDxR2h6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELR[mlKSzVyPUG5Mlc3PDJizszN	M4frbnNCVkeHUh?=
NUGC-3	NXjrfm1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTtTWM2OD1zOT65PFg4KM7:TR?=	MVjTRW5ITVJ?
5637	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTJyLkC0O\|gh\|ryP	MXTTRW5ITVJ?
NCI-H1755	MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjOTWM2OD1{MD60O\|Y1KM7:TR?=	MUDTRW5ITVJ?
RH-18	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjsN5VKSzVyPUKwMlU4PDhizszN	NYH4SGJ4W0GQR1XS
RXF393	NIjybXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfubGdKSzVyPUKwMlY4PTZizszN	NWT5OGRvW0GQR1XS
LU-134-A	NWTWXZlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4W2NmlEPTB;MkCuO\|A2PiEQvF2=	MYjTRW5ITVJ?
TE-12	MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTJyLkeyNFEh\|ryP	M3n1V3NCVkeHUh?=
MOLT-4	NFv5fIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;uTWM2OD1{MT6xPVE2KM7:TR?=	MorxV2FPT0WU
IGR-1	M1P5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYSye\|JkUUN3ME2yNU4{Pzl4IN88US=>	MVTTRW5ITVJ?
HOP-92	NFfRUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH:zdm1KSzVyPUKxMlQ6QDdizszN	NHrnV2VUSU6JRWK=
SK-MES-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\4TWM2OD1{MT63N\|gyKM7:TR?=	M1PUTHNCVkeHUh?=
LU-65	NWrFUXJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHQfZRKSzVyPUKxMlg3OjRizszN	NE\ScoZUSU6JRWK=
MS-1	NUHQOGRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTJ{LkGyNFMh\|ryP	NE\McZdUSU6JRWK=
LoVo	MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPo[4JNUUN3ME2yNk4zPDRizszN	NXi5Z4Q4W0GQR1XS
A704	M4LPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXGfo5KSzVyPUKyMlUyPTVizszN	NHOxR2JUSU6JRWK=
HT-1376	NELIRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTJ{Lk[wOVkh\|ryP	M{[0[nNCVkeHUh?=
IST-MEL1	M{\xUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{W5SmlEPTB;MkKuOlc2OSEQvF2=	M1jFSXNCVkeHUh?=
Ramos-2G6-4C10	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmT5TWM2OD1{Mj63N\|Y3KM7:TR?=	M3HuTnNCVkeHUh?=
T47D	Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTJ{Lke5O\|kh\|ryP	NFnwPWNUSU6JRWK=
HT-1197	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfyTWM2OD1{Mz6wPFE4KM7:TR?=	NX;xR3NMW0GQR1XS
LB2518-MEL	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPaTWM2OD1{Mz62OFEzKM7:TR?=	NGPEZ\|VUSU6JRWK=
J-RT3-T3-5	NHPqRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFyxRoVKSzVyPUK0Mlc2QTVizszN	MVjTRW5ITVJ?
SK-NEP-1	NVziepRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPOTWM2OD1{ND64O\|Q1KM7:TR?=	Mnm2V2FPT0WU
NCI-H526	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;rTWM2OD1{NT6wNFI{KM7:TR?=	M2jzVXNCVkeHUh?=
IST-SL1	M37Icmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mom5TWM2OD1{NT6yO\|UyKM7:TR?=	Mn3SV2FPT0WU
HH	MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2j5O2lEPTB;MkWuN\|E6OiEQvF2=	NESyfYFUSU6JRWK=
NCI-H82	NGjuWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTDbpdKSzVyPUK1Mlk{QCEQvF2=	MVPTRW5ITVJ?
SNU-449	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTJ5LkKwNVgh\|ryP	NH3Ke4xUSU6JRWK=
COR-L23	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTJ5LkK4NVMh\|ryP	MknmV2FPT0WU
LOXIMVI	Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVv4OY9bUUN3ME2yO{4{PjhizszN	MXLTRW5ITVJ?
GR-ST	MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoD4TWM2OD1{Nz62O\|A3KM7:TR?=	MljRV2FPT0WU
NCI-SNU-1	M2jqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTYbodXUUN3ME2yO{46PDRizszN	NXe2W2R3W0GQR1XS
ALL-PO	NVj4cVVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLVepB5UUN3ME2yPE4yPjB2IN88US=>	MmS4V2FPT0WU
ML-2	NXLObYRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHoTWM2OD1{OD6yPFE1KM7:TR?=	NG\UNIVUSU6JRWK=
HOP-62	M{XzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnX[ohKSzVyPUK4MlcyOyEQvF2=	NUTxRo1ZW0GQR1XS
EGI-1	NXWwVolsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\xTpd{UUN3ME2yPE45QDR3IN88US=>	MUHTRW5ITVJ?
TCCSUP	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHwTWM2OD1{OD65NlczKM7:TR?=	MlX5V2FPT0WU
LB996-RCC	M3O5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{CyOGlEPTB;MkmuOVY5OiEQvF2=	NXz0d3pZW0GQR1XS
LCLC-97TM1	NXvqSG4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjFfGVKSzVyPUOyMlE6PjRizszN	NUXJVJdnW0GQR1XS
NCI-H1304	MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTN{LkOzNFEh\|ryP	NYfHPYpZW0GQR1XS
KP-N-YS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;mTWM2OD1\|Mj61PVc{KM7:TR?=	M3uxZ3NCVkeHUh?=
NCI-H1770	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLnSZdGUUN3ME2zN{4yPjR6IN88US=>	MVTTRW5ITVJ?
EM-2	NF;wfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWOzPG1WUUN3ME2zN{43PTB2IN88US=>	NVH0OVBUW0GQR1XS
ChaGo-K-1	M2LWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzhPFdKSzVyPUOzMlczOzZizszN	M3XJbHNCVkeHUh?=
ACHN	NFPoNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXmRlBKSzVyPUOzMlg{QDVizszN	NXPscJZyW0GQR1XS
MN-60	NE\TboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX71Wm5HUUN3ME2zN{45PTR2IN88US=>	MnzTV2FPT0WU
EW-18	NW\JUmNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PNOWlEPTB;M{OuPFk4OSEQvF2=	M{DMOXNCVkeHUh?=
KGN	NInsbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvrfFRVUUN3ME2zOU44Ojl{IN88US=>	M2GwcnNCVkeHUh?=
U031	M3fmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVO2fFVNUUN3ME2zOU45OTN{IN88US=>	NVHoTHZ[W0GQR1XS
HMV-II	M4TlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;VSpNzUUN3ME2zOk4xPzd2IN88US=>	NIPMNHdUSU6JRWK=
L-363	NWL1SIdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXezcWV2UUN3ME2zO{43PDV3IN88US=>	NXLuUlBpW0GQR1XS
NCI-H1155	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PhWGlEPTB;M{iuNFAyPSEQvF2=	MnPWV2FPT0WU
NCI-H1793	NVLZSpdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTN6LkGwNlYh\|ryP	NETwcWtUSU6JRWK=
P30-OHK	M{\v[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYH2R4lnUUN3ME2zPE4yOzN{IN88US=>	Mn\DV2FPT0WU
AN3-CA	M17Rc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLW[VVKSzVyPUO4MlE3OTVizszN	M13LNnNCVkeHUh?=
UACC-257	M3H2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlW2TWM2OD1\|OD63PUDPxE1?	MWDTRW5ITVJ?
MCF7	NFnCZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVW3PYQ1UUN3ME2zPU45PjJ7IN88US=>	M4TtbnNCVkeHUh?=
KP-N-YN	M4D4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTYTWM2OD12MD60Nlg2KM7:TR?=	NYToOXE2W0GQR1XS
T98G	MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjzOXRKSzVyPUSwMlQ6PTdizszN	M{\K[HNCVkeHUh?=
HGC-27	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHkTWM2OD12Mz6yO\|Qh\|ryP	MY\TRW5ITVJ?
NCI-H1092	MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfQfWdKSzVyPUSzMlI5QTVizszN	MYLTRW5ITVJ?
KARPAS-299	NH3XellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTR\|LkOwO\|Eh\|ryP	NYrwVWY6W0GQR1XS
LB1047-RCC	NWHYZml{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3lPJJKSzVyPUS0Mlk6PTlizszN	NGDXbW5USU6JRWK=
786-0	MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Kz[GlEPTB;NEWuOlUh\|ryP	NIm1dFVUSU6JRWK=
HCC2157	MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTR4LkCzOVkh\|ryP	MXXTRW5ITVJ?
NY	NHTYNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHn3dWRKSzVyPUS2MlE4PzhizszN	MnjYV2FPT0WU
EFM-19	NELFcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fjW2lEPTB;NE[uO\|U{OyEQvF2=	M3PqcXNCVkeHUh?=
EW-16	M1LkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTR4Lke4NFYh\|ryP	NUnVUYM{W0GQR1XS
UM-UC-3	M320Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTR4LkiwOVkh\|ryP	NU\CeHFvW0GQR1XS
HT-29	M2jNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LFN2lEPTB;NEeuPFc6OiEQvF2=	MV3TRW5ITVJ?
LN-405	M4flSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\LSpJKSzVyPUS4MlA5OjdizszN	M4jMc3NCVkeHUh?=
NCI-H727	NI\WN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUS5[pZWUUN3ME20PE44PzJ4IN88US=>	MlP4V2FPT0WU
D-502MG	M13hPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3WwfWlEPTB;NEiuPVY4PiEQvF2=	MYrTRW5ITVJ?
GMS-10	MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXkUWZKSzVyPUS5MlI6PzRizszN	NETsd3hUSU6JRWK=
MEL-JUSO	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHP4dGtKSzVyPUS5MlM1PyEQvF2=	MUHTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-MEK / MEK / p-ERK / ERK / p-FAK(S910); PubMed: 23076151 J Biol Chem WM793 and WM793-Res NRAS cells were seeded overnight in the absence of PLX4720 and then treated with 1 μm PLX4720 for times ranging from 0 to 24 h. Samples were analyzed by Western blotting for phospho-MEK, total MEK, phospho-ERK1/2, total ERK1/2, phospho-S910 FAK, and total FAK. p-EGFR 1173 / EGFR / p-Akt / Akt; PubMed: 26023796 Oncotarget Three BRAF(V600E) glioma cell lines, NMC-G1, AM38 and DBTRG-05MG were subjected to a 24 hour time course treatment with 5 μM PLX4720 in the presence or absence of 1 μM HKI-272. These cells were serum starved for 16 hours before being stimulated with 10% FBS and harvested for immunoblotting analysis. Cells treated with PLX4720 alone showed an initial suppression of MEK and ERK phosphorylation followed by a profound rebound of MAPK pathway activation as early as one hour post-PLX4720 treatment. Elevated levels of EGFR phosphorylation were also observed in the PLX4720 treated cells. The extent of Akt phosphorylation increased upon PLX4720 treatment, although the extent varies between cell lines. In contrast, no reactivation of EGFR, MEK, ERK or Akt was observed in cells pre-treated with HKI-272. p27 / Cyclin D1 / pRb; PubMed: 21828154 Invest Ophthalmol Vis Sci Immunoblot analysis revealed that PLX4720 (3 μM) decreased levels of phosphorylated ERK, decreased levels of cyclin D1, increased levels of p27, and decreased levels of phosphorylated Rb in BRAF-mutant (OCM3) cells. On the contrary, in Gα-mutant (OMM1.3) UM cells, PLX4720 induced a paradoxical increase in phosphorylated ERK and Rb levels and an early increase in cyclin D1 levels but did not stimulate p27 levels. pAkt(Ser473) / pAkt(Thr308); PubMed: 21828154 Invest Ophthalmol Vis Sci Immunoblot analysis revealed that both AZD6244 and PLX4720 induced an early (within 2–6 hours of exposure) increase in the levels of phosphorylated Akt (at residues Ser473 and Thr308) in both BRAF-mutant OCM3 and Gα-mutant OMM1.3 cells. Eventually, and with prolonged drug exposure, the phosphorylation of Akt returned to baseline in Gα-mutant OMM1.3 cells and decreased even below baseline levels in BRAF-mutant OCM3 cells.	23076151 26023796 21828154
Immunofluorescence	LAMP1; PubMed: 30979895 Nat Commun Representative images of LysoTracker Red (red) and LAMP1 (green) immunostaining of PLX4720 (1 μM, 12 h-treated) A375 cells with depletion of the indicated genes. Note the reduced lysosome staining in PLX4720-treated cells upon TFEB depletion. ZKSCAN3 / TFEB ; PubMed: 30979895 Nat Commun Representative confocal images of subcellular translocation of endogenous TFEB (green) and ZKSCAN3 (red) in A375 cells treated with PLX4720 (1 μM, 12 h). n = 3 independent experiments.	30979895
Growth inhibition assay	Cell viability; PubMed: 27848137 J Neurooncol AM-38 and DBTRG-05MG cells were treated for 5 days. Media was changed once every 3 days. Cell viability was measured using WST-1 assay. Error bars indicate the variation between triplicate measurements. PLX4720 and PD0325901 alone or in combination reduced cell viability significantly. However, combined therapy led to the most significant cell viability reduction compared to either monotherapy in both AM-38 and DBTRG-05MG cell lines.	27848137
ELISA	mIFN-γ; PubMed: 23204132 Clin Cancer Res (C, D and E) IFN-γ secretion by pmel-1 T cells co-cultured with transduced melanoma cells (after cell sorting) that had been pre-treated with the indicated concentrations of PLX4720, as determined by ELISA. (P<0.05, * P<0.01) Data are representative of 3 independent experiments.	23204132

In vivo

Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays and regressions in B-Raf^V600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-Raf^V600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation. ^[1] PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, and dramatically decreases distant lung metastases. ^[3]

Protocol

Kinase Assay:^[1]	- Collapse In vitro Raf kinase activities: The in vitro kinase activities of wild type Raf and mutants are determined by measuring phosphorylation of biotinylated-MEK protein using Perkin-Elmer's AlphaScreen Technology. For each enzyme (0.1 ng), 20-μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl₂, 1 mM DTT, 0.01% Tween-20, 100 nM biotin-MEK protein, various ATP concentrations, and increasing concentrations of PLX-4720 at room temperature. Reactions are stopped at 2, 5, 8, 10, 20, and 30 minutes with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, and 0.3% BSA. The stop solution also includes phospho-MEK Antibody, Streptavidin-coated Donor beads and Protein A Acceptor beads from the AlphaScreen Protein A Detection Kit. The antibody and beads are preincubated in stop solution in the dark at room temperature for 30 minutes. The final dilution of antibody is 1/2,000, and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour then are read on a PerkinElmer AlphaQuest reader.
Cell Research:^[1]	- Collapse Cell lines: COLO205, A375, WM2664, COLO829, HT716, SW620, H460, Calu-6, HCT116, SK-MEL2, SK-MEL3, Lovo, H1299, 1205Lu, and C8161 cells Concentrations: Dissolved in DMSO, final concentrations ~1 mM Incubation Time: 24, 48, and 72 hours Method: Cells are treated with various concentrations PLX-4720 for 24, 48, and 72 hours. Cell proliferation is measured by using the CellTiter-Glo Luminescent Cell Viability Assay or MTT assay. For cell cycle analysis, supernatant and cells are collected, pelleted, and fixed with 70% ethanol. Before staining with propidium iodide (10 μg/mL), cells are incubated for 1 hour at 37 °C in 0.5 mg/mL RNase I to rid samples of residual RNA contamination. Samples are then analyzed by using the EPICS XL apparatus. For the assessment of apoptosis, media and cells are harvested and pelleted before staining with annexin-FITC and propidium iodide. Samples are subsequently analyzed by using the EPICS XL apparatus. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female athymic mice (NCr nu/nu) implanted s.c. with COLO205 cells, and SCID mice with 1205Lu or C8161 cells Dosages: 5, 20, or 100 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.56 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+50% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PLX-4720 SDF

Molecular Weight	413.83
Formula	C₁₇H₁₄ClF₂N₃O₃S
CAS No.	918505-84-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)Cl)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What would you recommend to make working solution for intraperitoneal injection into mice?
Answer:
PLX4720 has very limited solubility in aqueous solution and for this reason, we recommend oral gavage to administer this compound as not fully dissolved suspension can be used in oral gavage feeding.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. LY03009120 induces autophagy. Phase 1.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Dabrafenib (GSK2118436)

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.
Sorafenib

Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Sorafenib Tosylate

Sorafenib Tosylate (Bay 43-9006) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 (AR-00341677) is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted. GW5074 inhibits LK-induced apoptosis.

Choose Your Country or Region

By Signaling Pathways

By product type

PLX-4720